NCT06971107Not yet recruiting
Current Microsatellite Stability Results in Colon Cancer
TKRCD-MSI Study: Current Microsatellite Stability Findings in Colon Cancer - Nationwide Experience From Turkey
Source: ClinicalTrials.gov · Last updated 14 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes. The main questions it aims to answer are: * How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon? * How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery? * How do different types of dMMR (such as MLH1/PMS2 loss, MSH2/MSH6 loss, or sporadic cases) affect survival over three years? Participants will: * Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year. * Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment. This study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 6 May 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Turkish Society of Colon and Rectal Surgery
- Diseases
- Colorectal cancer
- NCT number
- NCT06971107
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 1 Jun 2025 to the primary completion date, 31 May 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non-adenocarcinoma malignancies of the colon (e.g., neuroendocrine tumors, lymphomas) Rectal cancers (defined as tumors within 15 cm of the anal verge on endoscopy or MRI) Incomplete medical or pathological records preventing classification of MMR status
Who the study is looking for
- Patients who have undergone curative-intent surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026 Surgery performed at a center with \>30 colon cancer surgeries per year Availability of MMR protein immunohistochemistry (IHC) and/or MSI test results from resection specimen and/or preoperative endoscopic biopsy Signed informed consent for participation and data collection
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| İstanbul Medipol University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
| Koc University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.